These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20877637)

  • 1. Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.
    Degl'Innocenti D; Alberti C; Castellano G; Greco A; Miranda C; Pierotti MA; Seregni E; Borrello MG; Canevari S; Tomassetti A
    PLoS One; 2010 Sep; 5(9):e12701. PubMed ID: 20877637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src inhibitors in suppression of papillary thyroid carcinoma growth.
    Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
    Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.
    Minna E; Romeo P; Dugo M; De Cecco L; Todoerti K; Pilotti S; Perrone F; Seregni E; Agnelli L; Neri A; Greco A; Borrello MG
    Oncotarget; 2016 Mar; 7(11):12731-47. PubMed ID: 26871295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Giannico A; Martinelli M; Marino C; Avenia N; Cristofani R; Farabi R; Reboldi G; Ribacchi R; Pontecorvi A; Santeusanio F
    Eur J Endocrinol; 2003 May; 148(5):505-13. PubMed ID: 12720532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.
    Zhang H; Teng X; Liu Z; Zhang L; Liu Z
    J Exp Clin Cancer Res; 2015 Feb; 34(1):16. PubMed ID: 25887589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma.
    Uddin S; Bavi P; Siraj AK; Ahmed M; Al-Rasheed M; Hussain AR; Ahmed M; Amin T; Alzahrani A; Al-Dayel F; Abubaker J; Bu R; Al-Kuraya KS
    Endocr Relat Cancer; 2010 Mar; 17(1):191-202. PubMed ID: 20008098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes.
    Endo T; Kobayashi T
    Endocr Relat Cancer; 2013 Dec; 20(6):767-76. PubMed ID: 24014739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor-β type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.
    He J; Jin Y; Zhou M; Li X; Chen W; Wang Y; Gu S; Cao Y; Chu C; Liu X; Zou Q
    Cancer Sci; 2018 Mar; 109(3):642-655. PubMed ID: 29274137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
    Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
    Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
    J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.
    Guarino V; Faviana P; Salvatore G; Castellone MD; Cirafici AM; De Falco V; Celetti A; Giannini R; Basolo F; Melillo RM; Santoro M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5270-8. PubMed ID: 15998773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
    Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
    PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
    Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
    Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of RET gene mediated EGFR signaling pathway on epithelial-mesenchymal transition, proliferation and apoptosis of papillary thyroid carcinoma cells.
    Zhao YL; Yuan BQ; Shen GS
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8036-8047. PubMed ID: 32767330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.
    Lin CI; Du J; Shen WT; Whang EE; Donner DB; Griff N; He F; Moore FD; Clark OH; Ruan DT
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E554-65. PubMed ID: 21190978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM; O'Leary JJ; Sweeney EC
    J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.